$0.56
+0.06 (+11.27%)
Open$0.51
Previous Close$0.50
Day High$0.57
Day Low$0.50
52W High$9.60
52W Low$0.58
Volume—
Avg Volume170.4K
Market Cap2.35M
P/E Ratio—
EPS$-13.50
SectorBiotechnology
Analyst Ratings
Strong Buy
7 analysts
Price Target
+816.9% upside
Current
$0.56
$0.56
Target
$5.14
$5.14
$3.59
$5.14 avg
$6.80
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 484.7K | 468.9K | 455.7K |
| Net Income | -93,000 | -114,838 | -98,507 |
| Profit Margin | -19.2% | -24.5% | -21.6% |
| EBITDA | -101,936 | -104,145 | -94,610 |
| Free Cash Flow | -84,967 | -104,034 | -103,597 |
| Rev Growth | +6.2% | -0.5% | +16.3% |
| Debt/Equity | 0.77 | 0.85 | 0.69 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $217.49 | +2.05% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $351.85 | +0.82% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $139.37 | +2.22% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $446.54 | +0.76% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $772.64 | +3.12% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $330.87 | +4.68% | 139.7 | 43.84B |